A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs E 2730 (Primary)
- Indications Epilepsy; Neurological disorders
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 01 Feb 2019 Status changed from recruiting to completed.
- 06 Sep 2018 Planned End Date changed from 6 Jun 2018 to 24 Oct 2018.
- 06 Sep 2018 Planned primary completion date changed from 6 Jun 2018 to 24 Oct 2018.